Status:

COMPLETED

Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects

Lead Sponsor:

Manjunath Prakash Pai

Collaborating Sponsors:

Hoffmann-La Roche

Conditions:

Obesity

Eligibility:

All Genders

18-50 years

Phase:

PHASE1

PHASE2

Brief Summary

One in three Americans are obese. Obese subjects may or may not need higher doses of the anti-flu drug known as Tamiflu (oseltamivir). The current study is being done to see if the FDA approved dose o...

Detailed Description

The incidence of obesity has increased dramatically over the past two decades in the United States (US). Twenty-five percent of adult Americans are now classified as obese. Obesity is associated with ...

Eligibility Criteria

Inclusion

  • males and females, 18 to 50 years of age
  • non-smoking or light-smoking (≤5 cigarettes per day) volunteers
  • BMI ≥ 40 kg/m2
  • female subjects of childbearing potential either surgically sterilized, using an effective method of contraception (diaphragm, cervical cap,condom) or agree to abstain from sex from time of pre-study screening, during entire study period and 1 week following the study period.

Exclusion

  • history of significant hypersensitivity reaction to oseltamivir
  • history of gastric bypass surgical procedure
  • history of significant clinical illness requiring pharmacological management
  • abnormal serum electrolyte or complete blood count requiring further clinical work-up
  • transaminases (AST or ALT) \>2.5 x upper limit of normal
  • estimated creatinine clearance \<50 mL/min (Cockcroft-Gault equation)
  • positive urine pregnancy test (if female)
  • abnormal electrocardiogram (ECG) as judged by study physician
  • unable to tolerate venipuncture and multiple blood draws
  • clinically significant abnormal physical examination defined as a physical finding requiring further clinical work-up

Key Trial Info

Start Date :

July 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2010

Estimated Enrollment :

21 Patients enrolled

Trial Details

Trial ID

NCT01179919

Start Date

July 1 2010

End Date

December 1 2010

Last Update

February 9 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

TKL Research

Paramaus, New Jersey, United States, 07652